Summary

Multiple Sclerosis Treatment Devices Market Research Report by Type [Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Relapsing-remitting Multiple Sclerosis (RRMS), Clinically Isolated Syndrome (CIS)], by Treatment Devices [Electrical Stimulation Devices (Functional Electrical Stimulation (FES), Transcutaneous Electrical Nerve Stimulation (TENS)), Neurostimulation Devices (Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS))], by End User (Hospitals & Clinics, Ambulatory Surgical Centers), and by Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Forecast till 2032

Market Overview
The Global Multiple Sclerosis Treatment Devices market was valued at USD 813.58 million in 2023 and is projected to reach USD 1,263.87 million by 2032. Multiple Sclerosis treatment devices are the medical tools that are specifically targeted to support MS patients in managing their symptoms. Multiple sclerosis is an autoimmune disease that is chronic which leads to the destruction of the central nervous system. Such devices are electrical stimulation systems, wearable rehabilitation aids, and mobility-support equipment. The purpose of such devices is to make moving easier for the user, to relieve pain, and to improve the quality of life of the patient.
The global Multiple Sclerosis (MS) Treatment Devices market is growing strongly as a result of the global increase in MS cases. According to the Atlas of MS 2023, nearly 2.9 million people with this disease reside in the world, which is an increase from 2.3 million in 2013. High prevalence rates in North America and Europe, particularly in countries like Canada, Norway, and the UK, are boosting demand for advanced therapeutic solutions.
The market is riding on the back of rapid developments in neurostimulation devices that include transcutaneous electrical nerve stimulation (TENS), spinal cord stimulation (SCS), and functional electrical stimulation (FES) systems, as well as wearable rehabilitation technologies. These solutions provide support in the control of deambulatory issues, decrease spasticity, and relieve symptoms of chronic pain while helping patients to be more independent. The creation of such AI-connected, cloud-connected devices that are monitoring continuously and adjusting treatment according to a patient's needs is one of the examples of the technological advances in neurostimulation devices.
Nevertheless, a lack of knowledge, insufficient health care structures, as well as high prices of the devices are the main problems in the less developed areas, resulting in the number of undiagnosed cases and low market penetration. As a result of collaborative efforts between healthcare providers and technology firms, this can be seen in several examples, such as AI-powered neuromodulation platforms and sensor-equipped wearables that automatically adjust to the user's motion, among others. Such partnerships are predicted to improve treatment accessibility, efficiency, and personalization, thus enabling the market to grow steadily over the next few years.

Market Segmentations
In terms of the treatment devices, the global market is segmented into electrical stimulation devices (ESD) and neurostimulation devices. Functional electrical stimulation and transcutaneous electrical nerve stimulation are further segments of the ESD. Spinal cord stimulation and deep brain stimulation are parts of neurostimulation devices.
The global multiple sclerosis treatment devices market is classified based on the type, comprising primary progressive multiple sclerosis, secondary progressive multiple sclerosis, relapsing-remitting multiple sclerosis, and clinically isolated syndrome.
Depending on the end users, the global multiple sclerosis treatment devices market is divided into hospitals & clinics, and ambulatory surgical centers.

Regional Insights
The North American leather market benefits from a top-notch presence of the automotive and fashion industries, which are premium. The U.S. remains a leading consumer, propelled by luxury upholstery demand and footwear production, while Canada contributes with specialty leather goods. Domestic tanners are transforming towards green processing so as to be in line with the new regulations. Asian imports fill up the gap for high-grade raw hides, and at the same time, export opportunities for finished leather products remain stable.
Europe has indeed a centuries-old heritage in leather craftsmanship, with Italy, France, and Spain as the main contributors. Luxury fashion houses, premium car interiors, and designer accessories are the main drivers of the region’s market. Strict environmental regulations force manufacturers to produce using chrome-free tanning and eco-certified processes. EU trade agreements facilitate the movement of raw material into the region as well as the transport of finished goods to other markets, hence better global competitiveness.
Asia-Pacific is indisputably the world leader in leather production, and China and India are undeniably the top tanning and manufacturing capacities. The combination of low production costs and plentiful raw materials is what drives exports of leather goods to Europe and North America. Domestic demand in emerging economies is on the rise, with increased incomes and urban fashion trends as the main factors. Sustainability ideas are becoming more and more well-known, especially in Japan and South Korea.
Brazil is the largest leather exporter in the South American region, and it is mainly focused on bovine hides. Argentina mostly supplies the premium leather industry with products that play a key role. Environmental issues and deforestation debates are some of the problems that the industry has to deal with, even though strong livestock production remains as a backbone of the industry. Demand from Asian buyers keeps the export market solid.
The Middle Eastern economy is flourishing with luxurious leather that has been imported from other countries, which are mainly for luxury products, and is driven by the consumers’ high purchasing power. Turkey and Egypt are the main production hubs for the region. Africa is the place where Ethiopia’s leather industry is growing with the establishment of industrial parks that are backed up by the government. But, still,

Major Players
Major competitors in the global multiple sclerosis treatment devices market are Medtronic, Abbott, Boston Scientific Corporation, Biotronik, Saluda Medical Pty Ltd., Enovis, Bayer, Koninklijke Philips N.V., BTL, and Axonics Inc.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ...... 20
2 MARKET INTRODUCTION ... 22
2.1 DEFINITION ........ 22
2.2 SCOPE OF THE STUDY ........... 22
2.3 RESEARCH OBJECTIVE .......... 22
2.4 MARKET STRUCTURE ........... 23
3 RESEARCH METHODOLOGY .................. 24
3.1 OVERVIEW ......... 24
3.2 DATA FLOW ....... 26
3.2.1 DATA MINING PROCESS ... 26
3.3 PURCHASED DATABASE: ...... 27
3.4 SECONDARY SOURCES: ........ 28
3.4.1 SECONDARY RESEARCH DATA FLOW: .... 29
3.5 PRIMARY RESEARCH: ........... 30
3.5.1 PRIMARY RESEARCH DATA FLOW: ........ 31
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED .......... 32
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE .............. 32
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ...... 33
3.6.1 REVENUE ANALYSIS APPROACH ............ 33
3.7 DATA FORECASTING............. 34
3.7.1 DATA FORECASTING TYPE ..................... 34
3.8 DATA MODELING .................. 35
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ... 35
3.8.2 DATA MODELING: ............. 36
3.9 TEAMS AND ANALYST CONTRIBUTION ..................... 38
3.10 INTRODUCTION ..................... 40
3.11 DRIVERS .............. 40
3.11.1 INCREASING PREVALENCE OF MULTIPLE SCLEROSIS (MS) ............... 40
3.11.2 ADVANCEMENTS IN NEUROSTIMULATION AND WEARABLE DEVICES ..................... 41
3.12 RESTRAINTS ....... 42
3.12.1 LIMITED AWARENESS AND ACCESSIBILITY IN DEVELOPING REGIONS .................... 42
3.13 OPPORTUNITY .. 44
3.13.1 RISING COLLABORATIONS BETWEEN HEALTHCARE PROVIDERS AND TECHNOLOGY FIRMS ......... 44
4 MARKET FACTOR ANALYSIS .................. 45
4.1 PORTER’S FIVE FORCES MODEL .............. 45
4.1.1 THREAT OF NEW ENTRANTS .................. 46
4.1.2 BARGAINING POWER OF SUPPLIERS ...... 46
4.1.3 THREAT OF SUBSTITUTES ..................... 46
4.1.4 BARGAINING POWER OF BUYERS ........... 46
4.1.5 INTENSITY OF RIVALRY .... 46
4.2 IMPACT OF COVID-19 ON THE GLOBAL MULTIPLE SCLEROSIS TREATMENT DEVICES MARKET ..... 47
5 GLOBAL MULTIPLE SCLEROSIS TREATMENT DEVICES MARKET, BY TYPE .... 49
5.1 OVERVIEW ......... 49
5.2 PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS) .............. 51
5.3 SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) ......... 51
5.4 RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) .............. 52
5.5 CLINICALLY ISOLATED SYNDROME (CIS) .................. 52
6 GLOBAL MULTIPLE SCLEROSIS TREATMENT DEVICES MARKET, BY TREATMENT DEVICES…. 53
6.1 INTRODUCTION ..................... 53
6.2 ELECTRICAL STIMULATION DEVICES .... 55
6.2.1 FUNCTIONAL ELECTRICAL STIMULATION (FES) ........... 55
6.2.2 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) ......... 56
6.3 NEUROSTIMULATION DEVICES ............... 56
6.3.1 SPINAL CORD STIMULATION (SCS) ........ 57
6.3.2 DEEP BRAIN STIMULATION (DBS) .......... 58
7 GLOBAL MULTIPLE SCLEROSIS TREATMENT DEVICES MARKET, BY END USER ................ 59
7.1 OVERVIEW ......... 59
7.2 HOSPITALS & CLINICS .......... 60
7.3 AMBULATORY SURGICAL CENTERS ....... 61
8 GLOBAL MULTIPLE SCLEROSIS TREATMENT DEVICES MARKET BY REGION . 62
8.1 OVERVIEW ......... 62
8.2 NORTH AMERICA .................. 64
8.2.1 US............... 67
8.2.2 CANADA ..... 69
8.3 EUROPE ............... 71
8.3.1 GERMANY ... 75
8.3.2 FRANCE ...... 77
8.3.3 UK .............. 78
8.3.4 SPAIN ......... 80
8.3.5 ITALY .......... 81
8.3.6 RUSSIA ....... 83
8.3.7 REST OF EUROPE .............. 85
8.4 ASIA PACIFIC ..... 87
8.4.1 CHINA ......... 91
8.4.2 INDIA .......... 92
8.4.3 JAPAN ........ 94
8.4.4 SOUTH KOREA .................. 96
8.4.5 MALAYSIA .. 97
8.4.6 THAILAND ... 99
8.4.7 INDONESIA .. 101
8.4.8 REST OF ASIA PACIFIC...... 103
8.5 SOUTH AMERICA ................... 105
8.5.1 BRAZIL ........ 109
8.5.2 MEXICO ...... 111
8.5.3 ARGENTINA ..................... 113
8.5.4 REST OF SOUTH AMERICA ..................... 115
8.6 MIDDLE EAST AND AFRICA . 117
8.6.1 GCC COUNTRIES............... 121
8.6.2 SOUTH AFRICA ................. 123
8.6.3 REST OF MEA ................... 125
9 COMPETITIVE LANDSCAPE .................... 128
9.1 INTRODUCTION ..................... 128
9.2 MARKET SHARE ANALYSIS, 2023 ............. 128
9.3 COMPETITOR DASHBOARD ..................... 129
9.4 PUBLIC PLAYERS STOCK SUMMARY ...... 130
9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ................ 130
9.1 KEY DEVELOPMENTS & GROWTH STRATEGIES ....... 131
9.1.1 PRODUCT LAUNCH ........... 131
9.1.2 PRODUCT APPROVAL ....... 131
10 COMPANY PROFILES ......... 132
10.1 ENOVIS ................ 132
10.1.1 COMPANY OVERVIEW ....... 132
10.1.2 FINANCIAL OVERVIEW ...... 133
10.1.3 PRODUCTS OFFERED ........ 133
10.1.4 KEY DEVELOPMENTS ........ 133
10.1.5 SWOT ANALYSIS .............. 134
10.1.6 KEY STRATEGIES .............. 134
10.2 AXONICS, INC. ... 135
10.2.1 COMPANY OVERVIEW ....... 135
10.2.2 FINANCIAL OVERVIEW ...... 136
10.2.3 PRODUCTS OFFERED ........ 137
10.2.4 KEY DEVELOPMENTS ........ 137
10.2.5 KEY STRATEGIES .............. 137
10.3 KONINKLIJKE PHILIPS N.V. .. 138
10.3.1 COMPANY OVERVIEW ....... 138
10.3.2 FINANCIAL OVERVIEW ...... 139
10.3.3 PRODUCTS OFFERED ........ 139
10.3.4 KEY DEVELOPMENTS ........ 140
10.3.5 SWOT ANALYSIS .............. 140
10.3.6 KEY STRATEGIES .............. 141
10.4 BTL .. 142
10.4.1 COMPANY OVERVIEW ....... 142
10.4.2 FINANCIAL OVERVIEW ...... 142
10.4.3 PRODUCTS OFFERED ........ 142
10.4.4 KEY DEVELOPMENTS ........ 143
10.4.5 KEY STRATEGIES .............. 143
10.5 BAYER AG ........... 144
10.5.1 COMPANY OVERVIEW ....... 144
10.5.2 FINANCIAL OVERVIEW ...... 145
10.5.3 PRODUCTS OFFERED ........ 145
10.5.4 KEY DEVELOPMENTS ........ 145
10.5.5 KEY STRATEGY ................. 146
10.6 MEDTRONIC ....... 147
10.6.1 COMPANY OVERVIEW ....... 147
10.6.2 FINANCIAL OVERVIEW ...... 148
10.6.3 PRODUCTS OFFERED ........ 149
10.6.4 KEY DEVELOPMENTS ........ 149
10.6.5 SWOT ANALYSIS .............. 150
10.6.6 KEY STRATEGIES .............. 150
10.7 ABBOTT ............... 151
10.7.1 COMPANY OVERVIEW ....... 151
10.7.2 FINANCIAL OVERVIEW ...... 152
10.7.3 PRODUCTS OFFERED ........ 152
10.7.4 KEY DEVELOPMENTS ........ 153
10.7.5 SWOT ANALYSIS .............. 153
10.7.6 KEY STRATEGIES .............. 154
10.8 BOSTON SCIENTIFIC CORPORATION ..... 155
10.8.1 COMPANY OVERVIEW ....... 155
10.8.2 FINANCIAL OVERVIEW ...... 156
10.8.3 PRODUCTS OFFERED ........ 157
10.8.4 KEY DEVELOPMENTS ........ 157
10.8.5 KEY STRATEGIES .............. 157
10.9 BIOTRONIK......... 158
10.9.1 COMPANY OVERVIEW ....... 158
10.9.2 FINANCIAL OVERVIEW ...... 158
10.9.3 PRODUCTS OFFERED ........ 159
10.9.4 KEY DEVELOPMENTS ........ 159
10.9.5 KEY STRATEGIES .............. 159
10.10 SALUDA MEDICAL PTY LTD. .................... 160
10.10.1 COMPANY OVERVIEW ....... 160
10.10.2 FINANCIAL OVERVIEW ...... 160
10.10.3 PRODUCTS OFFERED ........ 161
10.10.4 KEY DEVELOPMENTS ........ 161
10.10.5 KEY STRATEGIES .............. 161
11 DATA CITATIONS ................ 162
11.1 DATA CITATIONS ................... 163